Renal Function after Radioligand Treatment with 177Lu-PSMA-617

被引：0
|
作者：
Ngoc, Christina Nguyen [1 ]
Happel, Christian [1 ]
Davis, Karen [1 ]
Groener, Daniel [1 ]
Mader, Nicolai [1 ]
Mandel, Philipp [2 ]
Tselis, Nikolaos [3 ]
Gruenwald, Frank [1 ]
Sabet, Amir [1 ]
机构：
[1] Univ Hosp Frankfurt, Nucl Med, Frankfurt, Germany
[2] Univ Hosp Frankfurt, Urol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Radiooncol, Frankfurt, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1279
引用
收藏
页数：2
相关论文
共 50 条
  • [21] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [22] A Hangover Under 177Lu-PSMA-617 Therapy
    Poterszman, Nathan
    Somme, Laura
    Bund, Caroline
    Hutt, Emilie
    Somme, Francois
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 582 - 583
  • [23] Radiation Dosimetry in 177Lu-PSMA-617 Therapy
    Jackson, Price
    Hofman, Michael
    McIntosh, Lachlan
    Buteau, James Patrick
    Kumar, Aravind Ravi
    SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 243 - 254
  • [24] 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
    Tonnelet, David
    Edet-Sanson, Agathe
    Augusto, Laetitia
    Cabourg, Marine
    Thureau, Sebastien
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E668 - E669
  • [25] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [26] Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval
    Tuchayi, Abuzar Moradi
    Yadav, Surekha
    Jiang, Fei
    Kim, Sarasa T.
    Saelee, Rachelle K.
    Morley, Amanda
    Juarez, Roxanna
    Lawhn-Heath, Courtney
    Wang, Yingbing
    de Kouchkovsky, Ivan
    Hope, Thomas A.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (05) : 735 - 739
  • [27] 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy
    Clements, Sarah
    Tempesta, Daniel
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 213 - 214
  • [28] Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Sartor, Oliver
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 823 - 829
  • [29] Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617
    Wei, Xiao
    Schlenkhoff, Carl
    Sopora, Claudia
    Essler, Markus
    Ahmadzadehfar, Hojjat
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (11) : 894 - +
  • [30] Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Prasad, Vikas
    Heinzel, Aelxander
    Ruf, Juri
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang
    Krause, Bernd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345